吉西他滨联合顺铂及西艾克治疗晚期非小细胞肺癌临床疗效观察

A Clinical Study on the Combination of Gemcitabine,Cisplatin and Vindesine in the Treatment of Advanced Non-small Cell Lung Cancer

目的 :观察吉西他滨联合西艾克和顺铂治疗晚期非小细胞肺癌的疗效和毒副作用。方法 :对经病理组织学证实的 32例非小细胞肺癌患者给予吉西他滨 0 .8g/m2 静脉滴入 ,d1、d8、d15;西艾克 4mg静脉滴入 ,d1、d8;顺铂 30mg/m2 静脉滴入 ,d1～d3 ,2 8d为 1个周期。结果 :全组CR 2例 ,PR 12例 ,NC 11例 ,PD 7例 ,总有效率达 4 3 75 %。初治有效率达 5 6 2 5 % ,复治达 31 2 5 % ,两组经统计学比较 ,差异有显著性 (P <0 0 5 )。毒性反应为白细胞减少和血小板减少。结论 :吉西他滨联合顺铂和西艾克疗效较高 。

Objective To evaluate the efficacy and toxicity of the combination of Gemcitabine,cisplatin and vindesine in the treatment of patients with advanced non-small cell lung cancer (NSCLC).Methods Thirty-two patients with locally advanced (stage Ⅲb) or metastatic (stage Ⅳ) NSCLC were enrolled into the study.The patients received Gemcitabine 0.8 g/m 2 on day 1,8,15,vindesine 4mg on day 1,8,and cisplatin 30 mg/m 2 on day 1～3,administered in 28 day cycle.Results An objective response was obtained in 43.75% of patients (2 complete and 12 partial responses),whereas 11 patients had no change and 7 patients were progressive.The response rate was 56.25% in patients with no prior chemotherapy and the response rate of 31.25% was achieved in patients who had been given prior treatment.Significant difference existed between the two groups (P<0.05). The main toxicities were leukopenia and thrombocytopenia.Conclusion The combination of Gemcitabine,vindesine and cisplatin is a feasible,well-tolerated,and effective scheme in the treatment of advanced NSCLC.